RT Journal Article
SR Electronic
T1 A randomized, controlled, feasibility study of RD-X19 in patients with mild-to-moderate COVID-19 in the outpatient setting
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.17.21265058
DO 10.1101/2021.10.17.21265058
A1 Nathan Stasko
A1 Adam S. Cockrell
A1 Jacob F. Kocher
A1 Ibrahim Henson
A1 David Emerson
A1 Ye Wang
A1 Jonathan R. Smith
A1 Nathan H. Henderson
A1 Hillary Wood
A1 Shelton S. Bradrick
A1 Terry Jones
A1 Jorge Santander
A1 John G. McNeil
YR 2021
UL http://medrxiv.org/content/early/2021/10/25/2021.10.17.21265058.abstract
AB These studies aimed to further understand the antiviral effects of safe, visible light and demonstrate a therapeutic effect of an investigational treatment device for outpatients with mild to moderate COVID-19. RD-X19 is a handheld medical device precisely engineered to emit blue light through the oral cavity to target the oropharynx and surrounding tissues. At doses that are well-tolerated in an in vitro human epithelial tissue model, the monochromatic visible light delivered by RD-X19 results in light-initiated expression of IL-1α and IL-1β cytokines with corresponding inhibition of SARS-CoV-2 replication. A randomized, double-blind, sham-controlled early feasibility study using the investigational device enrolled 31 subjects with a positive SARS-CoV-2 antigen test and possessing at least two moderate COVID-19 signs and symptoms. Subjects were randomized 2:1 (RD-X19 to sham), treated twice daily for four days, and evaluated over one week. Prespecified outcome measures included assessments of SARS-CoV-2 viral load and clinical assessments of COVID-19. There were no local application site reactions and no device-related adverse events. The time-weighted average change in log viral load throughout the study demonstrated a favorable reduction for RD-X19 compared to sham and at the end of study the mean change in log10 viral load was -3.29 for RD-X19 and -1.81 for sham at Day 8, demonstrating a treatment benefit of -1.48 [95% confidence internal (CI), -2.88 to -0.071]. Among the clinical outcome measures, differences between RD-X19 and sham were also observed, with a 57-hour reduction of median time to sustained resolution of COVID-19 signs and symptoms.Competing Interest StatementStasko, Cockrell, Kocher, and Emerson report having/had employment relationships with EmitBio Inc. and being coinventors of patents broadly relevant to the disclosed work. McNeil and Henson report having employment relationships with EmitBio, Inc. Smith reported consulting fees from EmitBio Inc. during the conduct of the study. Drs. Jones and Santander reported investigator fees from EmitBio Inc. during the conduct of the study. No other disclosures were reported.Clinical TrialNCT04662671Funding StatementThis study was funded by EmitBio, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Advarra gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll publicly available data produced in the present work are contained in the manuscript.